Novartis increases its offer price on Novartis India Ltd.
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
This release is neither an offer to purchase nor a solicitation of an
offer to sell shares of Novartis India Ltd.
Basel, Switzerland, May 28, 2009 - Novartis announced today an
increase in the offer price for Novartis India Ltd. to Rs 450 per
share, from Rs 351 initially proposed.
The revised offer represents a premium of 63% to the closing share
price of Rs 275.6 of Novartis India Ltd. on March 24, which was the
last trading day before announcement of the offer.
This proposal represents Novartis' only and final price revision to
this offer, as May 28 is the last day on which the price can be
revised.
Disclaimer
This release contains certain forward-looking statements relating to
the proposed acquisition by Novartis of shares in Novartis India Ltd.
and to the respective businesses of Novartis and Novartis India Ltd.
Such forward-looking statements are not historical facts and can
generally be identified by the use of forward-looking terminology
such as "offer," or similar expressions, or by express or implied
discussions regarding the potential acquisition of Novartis India
Ltd. shares by Novartis; or by discussions of strategy, plans,
expectations or intentions or potential synergies, strategic benefits
or opportunities that may result from the proposed acquisition. You
should not place undue reliance on these statements. Such
forward-looking statements reflect the current plans, expectations,
objectives, intentions or views of Novartis with respect to future
events and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied
by such statements. There can be no guarantee that the proposed
acquisition will be completed in the expected form or within the
expected time frame or at all. Nor can there be any guarantee that
Novartis will achieve any particular future financial results or
future growth rates or that Novartis will be able to realize any of
the potential synergies, strategic benefits or opportunities as a
result of the proposed acquisition. Among other things, the
expectations of Novartis could be affected by unexpected regulatory
actions or delays or government regulation generally; competition in
general; government, industry and general public pricing pressures;
the impact that the foregoing factors could have on the values
attributed to the Novartis Group's assets and liabilities as recorded
in the Group's consolidated balance sheet, as well as other risks and
factors referred to in Novartis AG's Forms 20-F on file with the US
Securities and Exchange Commission. Novartis is providing the
information in this release as of this date and does not undertake
any obligation to update any forward-looking statements as a result
of new information, future events or otherwise.
This announcement is not an offer to purchase or the solicitation of
an offer to sell shares of Novartis India Ltd. Any offers to purchase
or solicitation of offers to sell will be made only pursuant to a
formal offer by Novartis. Shareholders are strongly advised to read
the terms of the offer carefully when they are available because they
will contain important information. Neither the offer to purchase
will be made to, nor will tenders pursuant to the offer to purchase
be accepted from or on behalf of, holders of shares in any
jurisdiction in which making or accepting the offer to purchase would
violate that jurisdiction's laws.
About Novartis
Novartis AG provides healthcare solutions that address the evolving
needs of patients and societies. Focused solely on healthcare,
Novartis offers a diversified portfolio to best meet these needs:
innovative medicines, cost-saving generic pharmaceuticals, preventive
vaccines, diagnostic tools and consumer health products. Novartis is
the only company with leading positions in these areas. In 2008, the
Group's continuing operations achieved net sales of USD 41.5 billion
and net income of USD 8.2 billion. Approximately USD 7.2 billion was
invested in R&D activities throughout the Group. Headquartered in
Basel, Switzerland, Novartis Group companies employ approximately
98,000 full-time-equivalent associates and operate in more than 140
countries around the world. For more information, please visit
http://www.novartis.com.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
e-mail: media.relations@novartis.com
Novartis Investor Relations
Central phone: +41 61 324 7944
Ruth +41 61 324 North America:
Metzler-Arnold 9980
Pierre-Michel +41 61 324 1065 Richard Jarvis +1 212 830
Bringer 2433
John Gilardi +41 61 324 3018 Jill Pozarek +1 212 830
2445
Thomas +41 61 324 8425 Edwin Valeriano +1 212 830
Hungerbuehler 2456
Isabella Zinck +41 61 324 7188
e-mail: e-mail:
investor.relations@novartis.com investor.relations@novartis.com
--- End of Message ---
Novartis International AG
Posfach Basel
WKN: 904278; ISIN:
CH0012005267; Index: SLCI, SMI, SPI, SLIFE;
Listed: Main Market in SIX Swiss Exchange, ZLS in BX Berne eXchange;